Improvement of Renal Function After Conversion to Mycophenolate Mofetil Combined With Low-Level Calcineurin Inhibitor in Liver Transplant Recipients With Chronic Renal Dysfunction

被引:20
作者
Ponton, C. [1 ]
Vizcaino, L. [1 ]
Tome, S. [1 ]
Otero, E. [1 ]
Molina, E. [1 ]
Castroagudin, J. F. [1 ]
Lopez-Lago, A. [1 ]
Varo Perez, E. [1 ]
机构
[1] Univ Hosp Santiago, Liver Transplantat Unit, Santiago De Compostela, Spain
关键词
CYCLOSPORINE MICROEMULSION; MONOTHERAPY; COMBINATION; IMPAIRMENT; TACROLIMUS; EFFICACY; FAILURE; DISEASE; RISK; ACID;
D O I
10.1016/j.transproceed.2010.02.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction. Calcineurin inhibitors (CNI) are the main pathogenic factors for renal dysfunction in solid organ transplant recipients. Introduction of non-nephrotoxic immunosuppressive drugs, such as mycophenolate mofetil (MMF), may allow discontinuation or reduction of CNI treatment, thereby improving renal function. The aim of this study was to assess the feasibility, efficacy and safety of MMF introduction and CNI dosage reduction in the maintenance immunosuppressive protocol to improve renal function in liver transplant recipients with chronic renal dysfunction. Patients and Methods. We prospectively included 88 liver transplant recipients including 74 men and an overall mean age of 58.8 +/- 10.3 years who all displayed chronic renal dysfunction (creatinine >1.4 mg/dL) and proteinuria <1 g/d. They were subdivided into 3 groups according to the basal creatinine value 1.4-1.7 mg/dL (group I; n = 41); 1.8-2.0 mg/dL (group II; n = 28); and >2 mg/dL (group III; n = 19). MMF was initiated at 1.5-2.0 g/d. Reduction of tacrolimus or cyclosporine dosage was performed to achieve respective target trough levels of <5 ng/mL or <50 ng/mL. We performed periodic determinations of arterial pressure, liver function tests, serum creatinine, blood cells count, CNI levels, and proteinuria. Results. Creatinine values after conversion were 1.4 +/- 0.5 mg/dL in the overall group. Improvement of renal function was more frequent among groups I (80.4%) and II (92.8%) versus III (73.6%). Normalization of creatinine values was more frequent in group I (68.2%) with respect to cohorts II (21.4%) and III (10.5%). Rejection was not detected. Conclusion. Application of an immunosuppressive protocol with MMF and low-level CNI in liver transplant recipients with chronic renal dysfunction was associated with improvement or normalization of creatinine, without an increased risk of rejection. Early conversion is needed to achieve the best results.
引用
收藏
页码:656 / 659
页数:4
相关论文
共 17 条
[1]  
ALLISON AC, 1993, TRANSPLANT P, V25, P67
[2]   Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil [J].
Barkmann, A ;
Nashan, B ;
Schmidt, HHJ ;
Böker, KHW ;
Emmanouilidis, N ;
Rosenau, J ;
Bahr, MJ ;
Hoffmann, MW ;
Manns, MP ;
Klempnauer, J ;
Schlitt, HJ .
TRANSPLANTATION, 2000, 69 (09) :1886-1890
[3]   Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction [J].
Cantarovich, M ;
Tzimas, GN ;
Barkun, J ;
Deschenes, M ;
Alpert, E ;
Tchervenkov, J .
TRANSPLANTATION, 2003, 76 (01) :98-102
[4]   LYMPHOCYTE-SELECTIVE CYTOSTATIC AND IMMUNOSUPPRESSIVE EFFECTS OF MYCOPHENOLIC-ACID INVITRO - ROLE OF DEOXYGUANOSINE NUCLEOTIDE DEPLETION [J].
EUGUI, EM ;
ALMQUIST, SJ ;
MULLER, CD ;
ALLISON, AC .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1991, 33 (02) :161-173
[5]   Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation [J].
Fisher, RA ;
Stone, JJ ;
Wolfe, LG ;
Rodgers, CM ;
Anderson, ML ;
Sterling, RK ;
Shiffman, ML ;
Luketic, VA ;
Contos, MJ ;
Mills, AS ;
Ferreira-Gonzalez, A ;
Posner, MP .
CLINICAL TRANSPLANTATION, 2004, 18 (04) :463-472
[6]   End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy - Risk of development and treatment [J].
Gonwa, TA ;
Mai, ML ;
Melton, LB ;
Hays, SR ;
Goldstein, RM ;
Levy, MF ;
Klintmalm, GB .
TRANSPLANTATION, 2001, 72 (12) :1934-1939
[7]   Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil [J].
Herrero, JI ;
Quiroga, J ;
Sangro, B ;
Girala, M ;
Gomez-Manero, N ;
Pardo, F ;
Alvarez-Cienfuegos, J ;
Prieto, J .
LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (05) :414-420
[8]   Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction [J].
Koch, RO ;
Graziadei, IW ;
Schulz, F ;
Nachbaur, K ;
Königsrainer, A ;
Margreiter, R ;
Vogel, W .
TRANSPLANT INTERNATIONAL, 2004, 17 (09) :518-524
[9]   Chronic renal failure after transplantation of a nonrenal organ [J].
Ojo, AO ;
Held, PJ ;
Port, FK ;
Wolfe, RA ;
Leichtman, AB ;
Young, EW ;
Arndorfer, J ;
Christensen, L ;
Merion, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :931-940
[10]   Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation [J].
Pageaux, Georges-Philippe ;
Rostaing, Lionel ;
Calmus, Yvon ;
Duvoux, Christophe ;
Vanlemmens, Claire ;
Hardgwissen, Jean ;
Bernard, Pierre-Henri ;
Barbotte, Eric ;
Vercambre, Lucille ;
Bismuth, Michael ;
Puche, Pierre ;
Navarro, Francis ;
Larrey, Dominique .
LIVER TRANSPLANTATION, 2006, 12 (12) :1755-1760